Teva, Medicis Strike Deal On Acne Drug Solodyn

Law360, New York (March 19, 2009, 12:00 AM EDT) -- Generic-drug maker Teva Pharmaceutical Industries Ltd. will stop shipping a popular anti-acne medication for the time being under a newly announced patent agreement with skin health specialist Medicis Pharmaceutical Corp., the companies announced Thursday.

But Teva has the option to market its generic versions of 45 mg, 90 mg and 135 mg Solodyn under the patent rights belonging to Medicis, commencing in November 2011, according to the drugmakers.

Solodyn is marketed as the first and only oral antibiotic approved to treat the inflamed pimples of moderate-to-severe...
To view the full article, register now.